DOACs Are Associated With Lower Recurrent VTE and Higher Nonmajor Bleeding Compared to Dalteparin
Direct oral anticoagulants (DOACs) are noninferior to dalteparin to prevent venous thromboembolism (VTE) recurrence in cancer patients, with similar rates of major bleeding but higher clinically relevant nonmajor bleeding (CRNMB) events, particularly in studies in which a larger proportion of patients with gastrointestinal (GI) cancer was enrolled.